Severe skin rash in case of readministration of telaprevir in a patient who previously experienced a non severe rash

Hepatology

Volumn 55, Issue 6, 2012, Pages 2042-2043

  Dupin, Nicolas ^a   Mallet, Vincent ^b   Carlotti, Agnès ^a   Vallet Pichard, Anaïs ^b   Pol, Stanislas ^b  

^a APHP Université Paris Descartes ^*  (France)

^b INSTITUT COCHIN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON; RIBAVIRIN; STEROID; TELAPREVIR;

ADULT; CASE REPORT; DISEASE SEVERITY; DRUG ERUPTION; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; LETTER; MEDICAL EXAMINATION; PRIORITY JOURNAL; SEVERE CUTANEOUS ADVERSE REACTION; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; EXANTHEMA; FEMALE; HEPATITIS C, CHRONIC; HUMANS; MIDDLE AGED; OLIGOPEPTIDES;

EID: 84861535035     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.25574     Document Type: Letter

References (4)

1. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417-2428.
2. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-2416.
3. Cacoub P, Bourlière M, Lübbe J, Dupin N, Buggisch P, Dusheiko G, et al. Dermatological side effects of hepatitis C and its treatment: patient management in the era of direct-acting antivirals. J Hepatol 2011 Aug 30. doi: 10.1016/j.jhep.2011.08.006.
4. Sarrazin C, Reesink HW, Zeuzem S, Weegink CJ, Luo D, Witek J, et al. Retreatment with telaprevir/Peg-IFN/RBV after a short exposure to telaprevir in phase I studies: interim results from a phase IIIb rollover trial (C219). HEPATOLOGY 2011; 54(SUPPL): 377A-378A.